From PvP Biologics Raises $35M in a Lab-to-Pharma Deal with Takeda:

KumaMax Enzyme (Image by Vikram Mulligan:Univ. Wash., used with permission)
KumaMax Enzyme (Image by Vikram Mulligan:Univ. Wash., used with permission)—

Computer-generated image of KumaMax Enzyme (Image by Vikram Mulligan:Univ. Wash., used with permission)

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Carbonite
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit/Ann Arbor, San Francisco, New York, Raleigh-Durham, Boulder/Denver, Texas, Wisconsin, Indiana, and beyond.

© 2007-2019, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.